Somewhat Favorable News Coverage Somewhat Unlikely to Impact Aquinox Pharmaceuticals (AQXP) Share Price

Press coverage about Aquinox Pharmaceuticals (NASDAQ:AQXP) has trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aquinox Pharmaceuticals earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.6825791459734 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Several brokerages have commented on AQXP. Canaccord Genuity set a $22.00 price target on shares of Aquinox Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, December 11th. Zacks Investment Research cut Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Needham & Company LLC reissued a “buy” rating and issued a $25.00 price target on shares of Aquinox Pharmaceuticals in a research note on Thursday, November 9th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $28.00 price target on shares of Aquinox Pharmaceuticals in a research note on Thursday, November 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $22.00.

Shares of Aquinox Pharmaceuticals (AQXP) traded down $0.14 during midday trading on Monday, hitting $11.51. The company had a trading volume of 29,100 shares, compared to its average volume of 68,500. The company has a market cap of $270.08, a PE ratio of -5.96 and a beta of -16.96. Aquinox Pharmaceuticals has a 1-year low of $10.02 and a 1-year high of $19.97.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last posted its earnings results on Wednesday, November 8th. The company reported ($0.50) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.62) by $0.12. analysts expect that Aquinox Pharmaceuticals will post -2.08 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Aquinox Pharmaceuticals (AQXP) Share Price” was first published by BBNS and is the property of of BBNS. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://baseballnewssource.com/markets/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-aquinox-pharmaceuticals-aqxp-stock-price/1817879.html.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Insider Buying and Selling by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets


Leave a Reply

 
© 2006-2018 BBNS.